Nieuwe economische analyse laat zien dat door FDA voorgestelde generieke medicijnetikettering wet tot $4 miljard aan nieuwe gezondheidskosten zou leiden

27 februari 2014

A recently proposed Food and Drug Administration (FDA) regulation affecting generic drug labeling would result in an estimated $4 billion in additional U.S. health care costs annually, according to a new analysis by economic consulting firm Matrix Global Advisors (MGA).
The FDA's Proposed Rule would permit generic drug manufacturers to initiate changes to their labels, which they currently are prohibited from doing. The agency insists that the rule would "generate little cost," but MGA finds that it would dramatically alter the legal and financial landscape for generic manufacturers and suddenly expose them to product liability lawsuits (Persbericht MGA, 5 februari 2014).
Klik hier voor het volledige persbericht.
Klik hier om het volledige rapport de downloaden (251 kB).

Dit bericht is ook opgenomen in ons maandelijkse overzicht, de NVC Members-only Update. Heeft u vragen, neem dan contact met ons op via e-mail of bel: +31-(0)182-512411